NASDAQ
06.02.26 | 22:00
3,770 US-Dollar
+5,60 % +0,200
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Shattuck Labs, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 28.01. | Piper Sandler stuft Shattuck Labs mit "Overweight" ein und sieht massives Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 28.01. | Piper Sandler initiates Shattuck Labs stock with Overweight rating | 1 | Investing.com | ||
| 22.01. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Why Shattuck Labs Stock Soared in December | 1 | The Motley Fool | ||
| 15.12.25 | Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 01.12.25 | Shattuck Labs stock rating upgraded to Buy by H.C. Wainwright | 2 | Investing.com | ||
| 07.11.25 | Shattuck Labs GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 06.11.25 | Shattuck Labs, Inc.: Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 201 | GlobeNewswire (Europe) | -First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers - - Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 - - Appointments... ► Artikel lesen | |
| 06.11.25 | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.10.25 | Shattuck Labs stellt auf UEG-Kongress innovativen Ansatz zur IBD-Behandlung vor | 1 | Investing.com Deutsch | ||
| 02.10.25 | Shattuck Labs, Inc.: Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel | 2 | GlobeNewswire (USA) | ||
| 26.08.25 | Shattuck Labs closes $103 million private placement led by OrbiMed | 2 | Investing.com | ||
| 26.08.25 | Shattuck Labs, Inc.: Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 26.08.25 | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08.25 | H.C. Wainwright maintains Neutral rating on Shattuck Labs stock as FDA clears IND | 2 | Investing.com | ||
| 21.08.25 | Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease | 390 | GlobeNewswire (Europe) | - SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases - - The Company... ► Artikel lesen | |
| 14.08.25 | Leerink Partners senkt Kursziel für Shattuck Labs auf 2 $ | 1 | Investing.com Deutsch | ||
| 14.08.25 | Shattuck Labs stock price target lowered to $2 by Leerink Partners | 1 | Investing.com |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUREXONE BIOLOGIC | 0,411 | -3,52 % | NurExone Biologics: Zwei dicke Fliegen auf einen Streich! | ||
| ONCO-INNOVATIONS | 0,535 | -0,93 % | Onco-Innovations meldet Einreichung eines vorläufigen Basisprospekts | Vancouver, Kanada - 4. Februar 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") gibt bekannt, dass es einen vorläufigen... ► Artikel lesen | |
| FRACTYL HEALTH | 0,420 | +5,00 % | Fractyl Health, Inc.: Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation | Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,770 Euro und damit +5,60 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.